Text Size

Inhibitory Receptors in Eosinophils of Atopic Subjects

This study is currently recruiting participants.
Verified April 2012 by Meir Medical Center
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01489293
First received: December 7, 2011
Last updated: March 3, 2013
Last verified: April 2012
History of Changes
  Purpose

The purpose of this study is to analyze the expression and activity of inhibitory molecules on eosinophils obtained from allergic subjects.


Condition
Atopy
Atopic Dermatitis
Asthma
Allergic Rhinitis
Food Allergy

Study Type: Observational
Study Design: Observational Model: Case Control
Official Title: Characterization of the Expression and Activity of Inhibitory Receptors Such as CLM-1 in Eosinophils of Atopic Subjects

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • Expression of surface molecules on eosinophils as assessed by flow cytometry [ Time Frame: December 2013 ] [ Designated as safety issue: No ]
    Blood samples from donors will be stained and evaluated by flow cytomtery


Biospecimen Retention:   Samples With DNA

whole blood


Estimated Enrollment: 40
Study Start Date: January 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
atopic subjects
Patients with one atopic disease or more (atopic dermatitis,rhinitis, asthma, food allergy)
non-atopic subjects
Control group without atopic diseases.

  Eligibility

Ages Eligible for Study:   20 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

allergy clinic

Criteria

Inclusion Criteria:

  • age 20-60 years
  • a physician-diagnosed atopic disease

Exclusion Criteria:

  • atopic disease not active
  • steroid treatment
  • active non-atopic inflammatory disease, including infections
  • pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01489293

Contacts
Contact: Alon Y Hershko, MD PhD 972-50-207-6448 alon.hershko@clalit.org.il

Locations
Israel
Meir Medical Center. Unit of Allergy and Clinical Immunology Recruiting
Kfar Saba, Israel
Principal Investigator: Alon Y Hershko, MD, PhD            
Sponsors and Collaborators
Meir Medical Center
Investigators
Principal Investigator: Alon Y Hershko, MD, PhD Meir Medical Center
  More Information

No publications provided

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01489293     History of Changes
Other Study ID Numbers: MMC110053CTIL
Study First Received: December 7, 2011
Last Updated: March 3, 2013
Health Authority: Israel: Ethics Commission

Additional relevant MeSH terms:
Asthma
Dermatitis
Dermatitis, Atopic
Food Hypersensitivity
Rhinitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
 Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Nose Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases

ClinicalTrials.gov processed this record on June 17, 2013